Skip to main content
Clinical Trials/JPRN-UMIN000011491
JPRN-UMIN000011491
Completed
未知

Multi-institution study on efficacy and safety of Propiverine Hydrochloride for female patients with urge and stress urinary incontinence - Female patients with uRgE and Stress urinary incontinence study of Propiverine Hydrochloride (FRESH)

Foundation for Biomedical Research and Innovation0 sites200 target enrollmentSeptember 1, 2013

Overview

Phase
未知
Intervention
Not specified
Conditions
mixed urinary incontinence
Sponsor
Foundation for Biomedical Research and Innovation
Enrollment
200
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 1, 2013
End Date
June 30, 2015
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)Patients with organ disease such as bladder stones, bladder tumors and urethral stricture in the lower urinary tract 2\)Patients with bacterial infections (i.e. bacterial cystitis) or nonbacterial infections (i.e. interstitial cystitis) 3\)Patients with advanced lower urinary tract obstruction or urinary retention 4\)Patients without urinary sensation 5\)Patients with overflow incontinence 6\)Patients with history or complications of pelvic organ prolapse 7\)Patients with pyloric, duodenal or intestinal obstruction 8\)Patients with gastric or intestinal atony 9\)Patients with angle\-closure glaucoma 10\)Patients with myasthenia gravis 11\)Patients with severe heart disease 12\)Patients with severe constipation 13\)Patients with dementia, who are not able to complete the questionnaires 14\)Patients with history of allergic reaction to Propiverine Hydrochloride or other similar medicine 15\)Patients with history of surgery that affect urination such as TOT or TVT 16\) Women who are pregnant, lactating, potentially pregnant or willing to get pregnant 17\)Patients with previous surgery of the abdomen and pelvis or radiation within 6 months 18\)Patients who started pelvic floor muscle exercise within 3 months 19\)Patients who took Propiverine Hydrochloride or other similar medicine within 2 weeks before entry 20\)Judged as being unsuitable for the trial by physician.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)
EUCTR2006-006522-25-BECSL Behring AG28
Active, not recruiting
Not Applicable
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)Patients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 yearsMedDRA version: 8.1Level: LLTClassification code 10010112Term: Common variable immunodeficiency
EUCTR2006-006522-25-DECSL Behring AG28
Active, not recruiting
Phase 1
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)Patients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 yearsMedDRA version: 8.1Level: LLTClassification code 10010112Term: Common variable immunodeficiency
EUCTR2006-006522-25-GRCSL Behring AG18
Active, not recruiting
Phase 1
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)
EUCTR2006-006522-25-GBCSL Behring AG18
Active, not recruiting
Not Applicable
A Multicenter study on the efficacy and safety of Vivaglobin in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID) - NDPatients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 years.MedDRA version: 6.1Level: PTClassification code 10057863
EUCTR2006-006522-25-ITCSL Behring AG28